Home Cardiology Coenzyme Q10 Doesn’t Prevent Periprocedural Myocardial Injury

Coenzyme Q10 Doesn’t Prevent Periprocedural Myocardial Injury

Findings among patients pretreated before elective percutaneous coronary intervention

MONDAY, July 25, 2016 (HealthDay News) — Pre-treatment with coenzyme Q10 (CoQ10) before elective percutaneous coronary intervention (PCI) does not reduce periprocedural myocardial injury (PMI), but does significantly decrease high-sensitivity C-reactive protein (hs-CRP) levels, according to a study published online July 6 in Cardiovascular Therapeutics.

Naser Aslanabadi, M.D., from the Tabriz University of Medical Sciences in Iran, and colleagues randomized 100 patients scheduled for elective PCI to receive a 300-mg loading dose CoQ10 12 hours before procedure. Creatine kinase-MB (CK-MB) and troponin-I levels were measured before procedure, and eight and 24 hours after, while hs-CRP was measured at baseline and 24 hours after.

The researchers observed no differences in CK-MB elevation (above the upper limit normal) between the two groups (P = 0.806). Similarly, elevated troponin-I was the same in both groups. There was no significant change seen in the level of cardiac biomarkers. However, a significant reduction in hs-CRP level occurred in the CoQ10 group (P = 0.032).

“The results showed that pretreatment with 300-mg CoQ10 12 hours before procedure could not [reduce] PMI following elective PCI; however, [it] significantly decreased hs-CRP, which can partially support the anti-inflammatory effects of CoQ10 in preventing PMI,” the authors write.

Full Text (subscription or payment may be required)

Copyright © 2016 HealthDay. All rights reserved.